TenNor Therapeutics (Suzhou) Limited (HKG:6872)

Market Cap	6.08B
Revenue (ttm)	n/a
Net Income	-160.84M
EPS	-3.82
Shares Out	52.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,800
Open	116.20
Previous Close	116.10
Day's Range	115.10 - 118.50
52-Week Range	75.70 - 287.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About HKG:6872

TenNor Therapeutics (Suzhou) Limited engages in discovery, development and commercialization of differentiated therapies for diseases associated with bacterial infections and bacterial metabolism. The company's offerings include drug production and medical research and experimental development, with a pipeline of products such as Rifasutenizole (TNP-2198) for treatment of Helicobacter pylori infection; Rifaquizinone (TNP-2092) injection for treatment of Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (AB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 56
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6872

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 30, 2026

Data Sources Report a data error